Standout Papers

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. 2001 2026 2009 2017 651
  1. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. (2001)
    Peter Bross, Julie Beitz et al. PubMed

Immediate Impact

10 by Nobel laureates 18 from Science/Nature 66 standout
Sub-graph 1 of 18

Citing Papers

The Rise of Boron-Containing Compounds: Advancements in Synthesis, Medicinal Chemistry, and Emerging Pharmacology
2024 Standout
Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras
2023 StandoutScienceNobel
11 intermediate papers

Works of Peter Bross being referenced

Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy
2003
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
2001 Standout

Author Peers

Author Last Decade Papers Cites
Peter Bross 588 676 458 12 1.4k
Haleh Saber 591 613 268 20 1.5k
Changpu Yu 658 719 183 22 1.5k
B Soehnlen 512 581 269 15 1.2k
M. A. Baker 398 695 248 18 1.5k
Janis Liebetanz 386 966 396 11 1.6k
Nida Iqbal 570 521 113 11 1.3k
Tiffany K. Ricks 754 524 239 20 1.7k
Audie Rice 648 818 519 28 1.6k
Beverly D. Smolich 396 962 471 17 1.7k
Melanie Cornejo 377 1009 273 19 1.6k

All Works

Loading papers...

Rankless by CCL
2026